Technology Bundle ID: NCI-E-026-2011

Diagnostics and Therapeutics for Adrenocortical Carcinomas

Request More Info
Licensing Contact:
Primary Inventors: 
Electron Kebebew ()
Application: 
Therapeutics
Development Status: 

Pre-clinical (in vivo)

The National Cancer Institute's Endocrine Oncology Branch seeks parties to co-develop diagnostic that target altered human miRNA expression such as miRNA-483 and miRNA 100 to accurately predict if a patient's adrenal cortex tumor is benign or malignant.

Adrenocortical carcinomas (ACC) are rare but aggressive cancers and typically have a poor prognosis.  Currently, there are limited options for molecular diagnosis to distinguish malignant tumors from benign tumors of this type.  As a result there are few treatment strategies for ACC.

This technology describes that altered human miRNA expression such as miRNA-483 and miRNA 100 can accurately predict if a patient''''s adrenal cortex tumor is benign or malignant. Additionally, preliminary results suggest that altering the expression of this miRNA in ACC cells can effect cancer cell growth.  Therefore, inhibiting a miRNA may serve as a therapeutic option for ACC.

Applications:
  • Technology can be developed into a diagnostic and prognostic marker for ACC.
  • Inhibiting miRNA can serve as a potential therapeutics for ACC.
Advantages:
  • Distinguishes malignant Adrenal cortex tumor from a benign tumor, options for such distinction are limited at this time.

Patents

U.S. Provisional Application 12/961,298
Filed on 2010-12-06

Publications

Patterson E, et al. MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy.
PMID: 21472710
Patterson E, et al. The microRNA expression changes associated with malignancy and SDHB mutation in pheochromocytoma.
PMID: 22241719